Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study.
No Thumbnail Available
All Authors
Roman, E.
Bagguley, T.
Crouch, S.
Smith, A.
Painter, D.
Howell, D.
Patmore, R.
Tooze, R.
Cargo, C.
De Tute, R.
LTHT Author
Tooze, Reuben
Cargo, Catherine
de Tute, Ruth
Rawstron, Andy
Cook, Gordon
Parrish, Christopher
Seymour, Frances
Cargo, Catherine
de Tute, Ruth
Rawstron, Andy
Cook, Gordon
Parrish, Christopher
Seymour, Frances
LTHT Department
Oncology
Leeds Cancer Centre
Haematological Malignancy Diagnostic Service
Haematology
Leeds Cancer Centre
Haematological Malignancy Diagnostic Service
Haematology
Non Medic
Consultant Clinical Scientist LeadClinical Scientist
Publication Date
2026
Item Type
Journal Article
Language
Subject
Subject Headings
Abstract
Monoclonal gammopathy of undetermined significance (MGUS) is a common plasma cell disorder with well described risks of progression to myeloma and lymphoplasmacytic lymphoma. Using data from an established UK population-based cohort of haematological malignancies and premalignancies, we investigated patient and disease characteristics, subsequent haematological malignancy, and survival in 4651 people diagnosed with MGUS 2005-2019. The 5-year net (relative) survival (disease-specific estimate of the probability of survival) of MGUS patients was 87.8% (95% Confidence Interval 85.9-89.7), with males (83.8%; 95% CI 81.0-86.6) more affected than females (92.2%; 95% CI 89.7-94.7). The proportion of subsequent haematological malignancies was also higher in males than females (8.8% versus 5.3%; P.
Journal
Haematologica